Elevai Labs signs licensing agreement with INmune Bio

Elevai Labs ( NASDAQ: ELAB ) said it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio ( INMB ). The agreement grants ELAB a license to use INMB's proprietary “EMx” technology, enabling ELAB to manufacture current Good Manufacturing Practice grade, human umbilical cord derived mesenchymal stromal cells at a lower cost.

Under the deal, ELAB will make an initial deposit for the license in two installments over six months, and a final tech transfer fee within two years of executing the agreement. The company will also pay a nominal royalty on the sale of licensed topical cosmetic products that are manufactured using the “EMx” technology.

More on Elevai Labs, Inc. Skincare company Elevai Labs sees stock dip 5% following $6M IPO.